The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. - Wikidata - awgldk - TriplyDB

The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.

The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.

http://www.wikidata.org/entity/Q46397598

about

Acute Kidney Injury in Patients with Cirrhosis Comparison of the effect of midodrine versus octreotide on hemodynamic status in cirrhotic patients with ascites Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and meta-analysis.Revision and update on clinical practice guideline for liver cirrhosis.A somatostatin analog improves tilt table tolerance by decreasing splanchnic vascular conductance Outcome of hepatectomy for hepatocellular carcinoma in patients with renal dysfunction Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial.Hyponatremia and Hepatorenal Syndrome Evaluation and management of patients with refractory ascites.Pathogenesis and management of alcoholic liver cirrhosis: a review.Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis Treatment of hepatorenal syndrome.Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS.Medical management of ascites.Managing complications in cirrhotic patients Management of hepatorenal syndrome.Hepatorenal Syndrome: Diagnosis and Treatment - newsreel.Systemic hemodynamic and renal effects of midodrine and octreotide in cirrhotic patients with ascites.Kidneys in chronic liver diseases.Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study.Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure.

P2860

Q26775643-EBA219F3-6CAC-43DC-A51E-A6E9395D919C Q34714014-50E59A2D-7C65-4CE7-A3B0-53CFF71C5726 Q34965513-1A5166B2-8AB7-4FEF-8CE7-724DC2FEE19F Q35859138-20C5732D-841E-4A1E-B0A3-7D8604D50781 Q35890613-033D3608-3D8D-4D2C-BF23-E653A535D0A6 Q35994705-59EB8467-6D19-4D8B-8EFB-0A3E930DB93E Q36063271-186C8BA6-D6B2-4050-8C4E-F1C8B8B2041C Q36422621-9D5C7AC6-59B8-4E52-A0AF-520848D40F90 Q36812531-91678BEC-0E60-4478-80AE-8633CBBA0A24 Q37122130-06E74389-9B01-4CED-A229-5BD4A250087D Q37355613-C8CFDA7D-84C5-462D-9853-C15C6D717DA5 Q37438171-7E07BED3-CF20-4EC9-86CC-3CB045CFDBAE Q37605883-67DF404E-BB37-4E78-9CBF-344CAF224B69 Q37789176-93FD746F-EB10-4659-9715-327938B9B9BD Q37838441-EB89FE62-A232-4611-AF94-4C4E4B580DF4 Q38344890-521CC766-0050-4F5A-89AC-FADED45C7F57 Q38463841-FD69D4C0-BCA6-4633-9E1C-17759D64E885 Q38961705-0226A530-6D17-453D-A347-68068D17A090 Q42323326-D3054337-A9F4-4C2E-B758-F4EA21FC3DAC Q43209206-935EFE10-E792-4D21-8E5B-0CC5E57B1287 Q51816090-40197EED-2927-4635-81D5-DEF4ECA89D01 Q53662298-F0A1FD30-8E16-4902-A79D-4F3579A496ED

P2860

The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.

http://www.wikidata.org/entity/Q46397598

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

The effects of chronic treatme ...... rrhotic patients with ascites.

@en

The effects of chronic treatme ...... rrhotic patients with ascites.

@nl

type

label

The effects of chronic treatme ...... rrhotic patients with ascites.

@en

The effects of chronic treatme ...... rrhotic patients with ascites.

@nl

prefLabel

The effects of chronic treatme ...... rrhotic patients with ascites.

@en

The effects of chronic treatme ...... rrhotic patients with ascites.

@nl

P1433

Q46397598-4F6320D4-AFE1-4B00-8BAE-CD2DD6B4A9AA

P1476

Q46397598-113ED93A-EA51-41D3-B2D7-30848FC074D6

P2093

Q46397598-192EFA2E-DA9F-47DC-91D2-237CEA21B1E9

Q46397598-2C02D18E-313F-46E6-9FBF-BC1CB8759A97

Q46397598-45EDCDF3-5B02-4BFF-81F0-90D53FEFAA8B

Q46397598-9576DBAB-765E-4683-B1E8-9DC081203DB3

Q46397598-986DC5CD-1EEA-4ABE-A3BA-0F7A5A593C33

Q46397598-AC68B5A6-0A95-419D-9D41-C02AD0B8A57F

Q46397598-C397B3ED-264C-4CF4-AE81-E1B31C3F27AE

P2860

Q46397598-13500533-A95E-4865-9D30-3B78F6359970

Q46397598-1DBCB2E5-846C-47E9-8C01-029F18492EA9

Q46397598-1E073033-4945-41B3-BA5E-CA83E6E4C871

Q46397598-1E73ABFE-CAE0-4361-8802-5F1F13C05EE5

Q46397598-23388B56-BD10-4374-BA8B-92A0B0BF7B51

Q46397598-389FE4B2-1E97-47FB-8D5A-E25E7E2A571A

Q46397598-6596A0F9-1993-44F7-9B50-0134B76A3719

Q46397598-67706872-014B-4FDC-8BFE-37493D063CD5

Q46397598-72736495-273C-4F87-B547-ED9B22FAF8D2

Q46397598-9C8C8FDB-E7CD-444E-8C77-7600677108B4

P304

Q46397598-A558E03E-5066-4C98-A3F2-116FC700D151

P31

Q46397598-BE084CD7-C696-485F-ADB6-6D8AD66E427C

P356

Q46397598-C5C417B0-889D-46BC-B0D4-A474AD8D6915

P407

Q46397598-AD736848-EC74-4AC8-87B4-B632979F0437

P433

Q46397598-52394AA7-F36B-4F42-92FC-6DC9BB4B5EC0

P478

Q46397598-74FE97CA-0152-4F96-8D48-DEB42504C27C

P577

Q46397598-4A8DC86B-78C4-453D-8445-6B9F6DB149FE

P5875

Q46397598-EB2BADD0-0D14-40FA-BA2D-8484C5B5E34C

P698

Q46397598-DE140FEB-89E4-44C9-B292-2DAD8A00A59E

P921

Q46397598-830C129B-E1DF-4C0E-814A-E872A8238766

Q46397598-ED55191D-76FD-448F-8E73-0C7509881853

P356

J.1572-0241.2005.40899.X

P1433

The American Journal of Gastroenterology

P1476

The effects of chronic treatme ...... rrhotic patients with ascites.

@en

P2093

Afroditi Katsaraki

http://www.w3.org/2001/XMLSchema#string

Andreas Fotopoulos

http://www.w3.org/2001/XMLSchema#string

Christos Pappas

http://www.w3.org/2001/XMLSchema#string

Epameinondas V Tsianos

http://www.w3.org/2001/XMLSchema#string

Georgios Kalambokis

http://www.w3.org/2001/XMLSchema#string

Jihad Al Bokharhii

http://www.w3.org/2001/XMLSchema#string

Michalis Economou

http://www.w3.org/2001/XMLSchema#string

P2860

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.

Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.

Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.

Inhibition of frusemide-induced hyperreninaemia by growth-hormone release-inhibiting hormone in man.

Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.

SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function.

Effect of somatostatin on plasma renin activity.

Cardiovascular effects of octreotide in patients with hepatic cirrhosis.

P304

879-885

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1572-0241.2005.40899.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7951172

http://www.w3.org/2001/XMLSchema#string

P698

15784036

http://www.w3.org/2001/XMLSchema#string

P921